A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
NCT05347485
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is looking at a new drug called cilta-cel to see if it works well and is safe for people to use, even if it doesn't meet all the usual requirements.
This study is looking at a new drug called cilta-cel to see if it works well and is safe for people to use, even if it doesn't meet all the usual requirements.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
